Melasma

Acquired, chronic hypermelanosis characterized by symmetrical, irregularly bordered hyperpigmented macules and patches

Epidemiology

  • Common in women of reproductive age
  • Female : male ≈ 9 : 1
  • More prevalent in Fitzpatrick skin types III–V
  • Higher incidence in tropical regions
  • Strong association with sun exposure, pregnancy, and hormonal factors

Aetiology

  • Ultraviolet (UV) radiation (most important)
  • Hormonal influences:
    • Pregnancy (chloasma)
    • Oral contraceptives
  • Genetic predisposition
  • Photosensitizing drugs and cosmetics
  • Thyroid dysfunction (association)

Pathophysiology

  • Hyperfunctional melanocytes with normal cell count
  • Increased melanin synthesis and transfer
  • UV exposure induces:
    • ↑ α-MSH
    • ↑ tyrosinase activity
    • Dermal inflammation and vascular changes

Clinical presentation

  • Symmetric, irregularly shaped brown to gray-brown macules/patches
  • Well-defined but irregular borders
  • No scaling, erythema, or symptoms
  • Gradual onset, chronic course
  • Exacerbated by sun exposure
notion image

Investigations

  • Clinical diagnosis
  • Wood’s lamp: helps determine pigment depth (limited in darker skin)
  • Dermoscopy: reticulated brown pigmentation
  • Biopsy: rarely required

Management

General Measures (Cornerstone)

  • Strict photoprotection
    • Broad-spectrum sunscreen (SPF ≥30–50)
    • Physical blockers (zinc oxide, titanium dioxide)
    • Protective clothing

Topical Therapy (First-line)

Agent
Mechanism
Hydroquinone 2-5%
Tyrosinase inhibition
Triple combination cream
Hydroquinone + tretinoin + corticosteroid
Azelaic acid 20%
Inhibits tyrosinase
Kojic acid
Melanin inhibition
Retinoids
Increase epidermal turnover

Procedural Therapy

  • Chemical peels (glycolic, salicylic acid)
  • Laser and light-based therapy (with caution)
  • Microneedling (adjunctive)